Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Severe/Very Severe COVID-19 Illness”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Not applicableNo Longer AvailableNCT04337359
What this trial is testing

Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

Who this might be right for
Severe/Very Severe COVID-19 Illness
Novartis Pharmaceuticals
Not applicableAvailableNCT04745637
What this trial is testing

Managed Access Programs for INC424, Ruxolitinib

Who this might be right for
Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Thrombocythemia Myelofibrosis (PET-MF)+4 more
Novartis Pharmaceuticals